⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VRDN News
Viridian Therapeutics, Inc. Common Stock
Viridian Therapeutics Prepares for Transformational 2026
businesswire.com
VRDN
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
businesswire.com
VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
VRDN
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
businesswire.com
VRDN
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
businesswire.com
VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
VRDN